Ustekinumab: in psoriasis and beyond :a derm atological perspective
Publication details: New York SAGE 2024Edition: Vol.15(2), JunDescription: 105-121pSubject(s): Online resources: In: Journal of pharmacology and pharmacotherapeuticsSummary: Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy. Purpose This review aims to describe the dermatological implications and applications of ustekinumab. Methodology PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions.| Item type | Current library | Status | Barcode | |
|---|---|---|---|---|
Articles Abstract Database
|
School of Pharmacy Archieval Section | Not for loan | 2025-0262 |
Ustekinumab is an interleukin 12/23 inhibitor, approved by the US-FDA for the management of moderate-to-severe plaque psoriasis and psoriatic arthropathy.
Purpose
This review aims to describe the dermatological implications and applications of ustekinumab.
Methodology
PubMed and Google Scholar were searched for scholarly articles related to ustekinumab and its utility in dermatology using the search terms “Ustekinumab” AND “Psoriasis” AND “dermatological diseases”. Studies utilising Ustekinumab in psoriasis and other dermatological indications were analysed and formulated into a systematic review discussing the utility of the drug in psoriasis, as well as other dermatological conditions.
There are no comments on this title.
Click on an image to view it in the image viewer